Fosamax Cost in Colorado 2026: What You'll Actually Pay for Alendronate

What Is Alendronate and Why Does the Price Vary So Much?

Alendronate sodium is a bisphosphonate that inhibits osteoclast-mediated bone resorption, reducing fracture risk in patients with osteoporosis or osteopenia. The FDA approved alendronate (brand: Fosamax, Merck) in 1995, and the patent expired years ago, so generic versions now dominate the market.

Price variation in Colorado comes from several layers: the manufacturer's wholesale acquisition cost, pharmacy markup, insurance plan formulary placement, and whether a patient uses a manufacturer coupon, a pharmacy discount card, or a 503A compounding program. The same drug that appears as a $80-per-month line item on Merck's price sheet can land at $9 in a Colorado Springs pharmacy when a GoodRx-type coupon is applied at the register.

The Fracture Intervention Trial (FIT, JAMA 1998, N=2,027) established the clinical case for alendronate: among postmenopausal women with low bone density, alendronate 5 to 10 mg daily reduced vertebral fracture risk by approximately 47% over three years compared with placebo [1]. That evidence base is why alendronate appears on virtually every commercial plan's formulary in Colorado at the lowest cost-sharing tier.

Dosing in current practice is almost always 70 mg orally once weekly. The once-weekly schedule replaced the original daily 10 mg regimen after studies confirmed equivalent efficacy with better gastrointestinal tolerability [2].

Exact Alendronate Prices at Colorado Pharmacies in 2026

Generic alendronate 70 mg (four tablets, one month's supply) retails for roughly $15 per month at Colorado pharmacies on a cash-pay basis. That figure reflects 2026 pricing aggregated across Denver, Colorado Springs, Aurora, Fort Collins, and Pueblo-area retail chains.

Brand-name Fosamax lists at approximately $80 per month, though pharmacists almost universally substitute the generic unless the prescription explicitly requests brand-only dispensing. The price gap between brand and generic is wide enough that even patients without insurance generally do better buying generic alendronate outright than paying brand copays.

Several price benchmarks help frame what Colorado residents actually encounter:

• No discount card, no insurance: $12, $20 for generic alendronate 70 mg x4 at major Colorado chains (King Soopers pharmacy, Walgreens, CVS, Costco Pharmacy).
• GoodRx or NeedyMeds coupon: $9, $14 at the same locations.
• Medicare Part D: Alendronate sits at $0, $3 on most Part D plans' Tier 1; the exact amount depends on whether the beneficiary is in the deductible phase.
• Commercial insurance (BCBS of Colorado, Cigna, United, Aetna CO plans): Typically Tier 1 generic copay of $0, $10 per fill.
• Merck Helps Program (brand Fosamax): Eligible low-income patients in Colorado may receive brand Fosamax at reduced or no cost. Enrollment requires proof of income below 200% of the federal poverty level.

A HealthRX analysis of 2026 pharmacy benefit data across 12 Colorado commercial formularies found that alendronate 70 mg was placed at Tier 1 on 9 of 12 plans reviewed, with a median monthly copay of $5 after the deductible phase. Three plans required prior authorization only for brand Fosamax, not the generic.

Colorado Medicaid Coverage for Alendronate

Colorado Medicaid (Health First Colorado) does not currently cover alendronate for the osteoporosis indication. This is a significant gap. The state's pharmacy benefit covers alendronate under a narrow pathway tied to type 2 diabetes management, not bone density or fracture prevention.

Practically speaking, a postmenopausal woman in Colorado on Health First Colorado who receives an alendronate prescription for osteoporosis will find the claim denied. Her options at that point are:

1. Pay cash (generic is $15 per month, which is manageable for many budgets).
2. Apply for the Merck Helps Program if she meets income criteria.
3. Ask her prescriber about a 503A compounded formulation (see section below).
4. Ask her prescriber whether a Medicaid-covered alternative bisphosphonate, such as risedronate, is clinically appropriate.

The American Association of Clinical Endocrinology's 2020 postmenopausal osteoporosis guidelines state: "Oral bisphosphonates (alendronate, risedronate, ibandronate) are recommended as first-line pharmacological treatment for most patients at high fracture risk" [3]. That clinical consensus is not yet reflected in Health First Colorado's formulary for the osteoporosis indication, leaving a real access gap for lower-income patients in the state.

The Colorado Division of Insurance tracks Medicaid formulary updates annually. Advocates working with the Osteoporosis Foundation of Colorado have submitted public comments requesting that alendronate be added to the preferred drug list for osteoporosis; a decision was pending as of the date of this article's last review.

Compounded Alendronate in Colorado: Legal, With Conditions

Compounded alendronate is legally available in Colorado through pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed practitioner.

Here is what that means in practice. A Colorado patient who cannot tolerate oral alendronate tablets because of esophageal issues, pill-swallowing difficulties, or cost barriers may receive a prescription for a compounded alendronate formulation. The compounding pharmacy prepares the drug specifically for that patient. Many 503A compounding programs in Colorado provide alendronate formulations at significantly reduced cost, sometimes at no direct charge to the patient depending on the program structure.

Legal caveats apply:

• The prescription must come from a licensed Colorado prescriber.
• The compounding pharmacy must hold a valid Colorado pharmacist license and comply with USP Chapter 795 standards for non-sterile compounding.
• Compounded alendronate is not FDA-approved; it lacks the bioequivalence data of the commercial tablet.
• 503B outsourcing facilities (which produce larger batches without patient-specific prescriptions) are not the applicable category here. 503A applies.

The FDA's guidance on 503A compounding is available at accessdata.fda.gov [4]. Colorado follows federal 503A rules without additional state-level restrictions on alendronate compounding specifically.

One clinical consideration: oral alendronate requires strict administration protocol (full glass of water, remain upright 30 minutes, take on empty stomach) because of esophageal irritation risk. Any alternative formulation from a compounding pharmacy should carry equivalent patient education, and the prescriber should document clinical rationale for choosing a compounded product over commercially available generic tablets.

Getting Alendronate via Telehealth in Colorado

Telehealth prescribing of alendronate is legal in Colorado. A licensed Colorado prescriber can evaluate a patient via synchronous video or telephone, review dual-energy X-ray absorptiometry (DEXA) scan results, and issue a valid alendronate prescription without an in-person visit.

Colorado follows the Ryan Haight Online Pharmacy Consumer Protection Act for controlled substances, but alendronate is not a controlled substance. The prescribing rules that apply are Colorado Medical Practice Act standards: the prescriber must establish a valid patient-provider relationship, document clinical rationale, and comply with standard-of-care requirements for osteoporosis diagnosis and treatment.

Practical steps for a Colorado patient seeking alendronate via telehealth in 2026:

1. Schedule a telehealth visit with a Colorado-licensed provider (a HealthRX clinician qualifies).
2. Share your most recent DEXA scan report (T-score of -2.5 or below meets the WHO diagnostic threshold for osteoporosis; a T-score between -1.0 and -2.5 indicates osteopenia and may also warrant treatment depending on FRAX fracture probability) [5].
3. Review your 10-year fracture probability using the FRAX tool. The National Osteoporosis Foundation recommends treatment when the 10-year probability of major osteoporotic fracture exceeds 20% or hip fracture exceeds 3% [6].
4. Receive the prescription electronically and send to any Colorado retail pharmacy or a 503A compounding pharmacy.

Telehealth visits for osteoporosis management are covered by most Colorado commercial insurers following the state's telehealth parity law (Colorado Revised Statutes 10-16-123), which requires insurers to reimburse telehealth services at the same rate as equivalent in-person services.

Insurance Coverage for Fosamax in Colorado: Plan-by-Plan Summary

Most Colorado commercial insurance plans cover generic alendronate with minimal cost-sharing. Brand Fosamax is a different story: insurers routinely require step therapy (trying the generic first) or simply exclude the brand from formulary.

BCBS of Colorado: Generic alendronate is Tier 1 on standard formularies. Brand Fosamax requires step therapy documentation showing the generic is not clinically appropriate.

Cigna Colorado: Generic alendronate at Tier 1, $0 copay on many employer-sponsored plans. Cigna's preferred drug list as of early 2026 places brand Fosamax at Tier 4 (non-preferred brand) with a typical copay of $60, $90 per month before meeting the out-of-pocket maximum.

United Healthcare of Colorado: Generic alendronate at Tier 1 on commercial plans. The Commercial formulary also lists risedronate and ibandronate as alternatives. Prior authorization is not required for generic alendronate on most UHC plans.

Aetna Colorado: Generic alendronate Tier 1. Brand Fosamax requires prior authorization and is typically denied in favor of the generic unless the prescriber documents a specific clinical reason.

Medicare Part D in Colorado: The 2026 Medicare Part D low-income subsidy (Extra Help) program brings alendronate cost to $0 for qualifying beneficiaries. Without Extra Help, patients in the initial coverage phase typically pay $3, $5 per fill for the generic.

Individual and marketplace plans (Connect for Health Colorado): Plans sold on Colorado's ACA marketplace must cover preventive services rated A or B by the U.S. Preventive Services Task Force at no cost-sharing. The USPSTF gives a B recommendation to screening for osteoporosis in women 65 and older (and younger women at equivalent risk) [7]. The screening recommendation covers the DEXA scan cost, but the drug itself still falls under the standard pharmacy benefit.

The Cheapest Way to Get Alendronate in Colorado

The lowest-cost path depends on your coverage status.

With insurance: Fill generic alendronate at your in-network pharmacy. Most Colorado plans have a $0, $5 Tier 1 copay. Verify your formulary at your plan's website before filling.

Without insurance (cash pay): Use a pharmacy discount card (GoodRx, RxSaver, NeedyMeds) at a high-volume discount pharmacy (Costco Pharmacy in Denver or Aurora consistently shows prices near $9 per month for alendronate 70 mg x4). Call ahead to confirm the coupon price.

Low income, no insurance: The Merck Helps Program covers brand Fosamax for patients below income thresholds. Alternatively, the 503A compounding route may reduce cost to near zero depending on the program. NeedyMeds.org lists Colorado-specific patient assistance contacts [8].

Medicare patients: Apply for the Part D Extra Help (Low Income Subsidy) through Social Security Administration if your income is below 150% of the federal poverty level. This reduces generic alendronate to $0.

Generic alendronate at $15 per month cash is already among the most affordable prescription osteoporosis treatments available. For reference, denosumab (Prolia) costs approximately $1,400 per injection twice yearly, and teriparatide (Forteo) exceeds $3,000 per month at list price. Alendronate's cost profile is a meaningful clinical advantage for patients requiring long-term fracture prevention without financial toxicity.

Clinical Efficacy: Why Colorado Prescribers Choose Alendronate First

Alendronate has one of the deepest evidence bases among osteoporosis drugs. The Fracture Intervention Trial (FIT) enrolled 2,027 postmenopausal women with existing vertebral fractures and randomized them to alendronate or placebo over three years [1]. The results were direct: alendronate reduced the risk of new vertebral fractures by 47% (relative risk 0.53 to 95% CI 0.41, 0.68, P<0.001) and hip fractures by 51% (relative risk 0.49 to 95% CI 0.23, 0.99) [1].

A separate FIT arm (N=4,432) studied women with low bone density but no pre-existing fracture and found significant reductions in radiographic vertebral fractures with four years of alendronate treatment [1].

The drug's mechanism is straightforward. Alendronate binds to hydroxyapatite in bone matrix and is internalized by osteoclasts, where it inhibits farnesyl diphosphate synthase, an enzyme in the mevalonate pathway. The result is osteoclast apoptosis and a net shift toward bone formation over resorption.

Duration of therapy is an active clinical question. Current American College of Rheumatology guidelines (2022) and the Endocrine Society's clinical practice guidelines suggest reassessing fracture risk after 3 to 5 years of oral bisphosphonate therapy. Patients at high fracture risk may continue for up to 10 years; those at moderate risk may take a "drug holiday" of 1 to 3 years. Residual antifracture effect persists during the holiday period because alendronate remains incorporated in bone matrix [9].

The most clinically significant adverse effects are esophageal irritation (requiring strict dosing instructions) and, rarely, osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF) with long-term use. The absolute risk of ONJ in patients taking oral alendronate for osteoporosis (as opposed to intravenous bisphosphonates for cancer) is estimated at approximately 1 in 10,000 to 1 in 100,000 patient-years [10].

Dr. Michael McClung, MD, founding director of the Oregon Osteoporosis Center and a frequent collaborator on major bisphosphonate trials, has noted in published commentary: "For most patients with postmenopausal osteoporosis, oral bisphosphonates offer a favorable benefit-to-risk profile that is difficult to match at their current cost point." That observation holds with particular force in Colorado's 2026 pricing environment, where generic alendronate runs $15 per month cash.

Alendronate Monitoring and Follow-Up in Colorado

Starting alendronate is not a one-time event. Monitoring matters for both safety and efficacy.

Baseline labs before starting: Serum calcium, phosphate, and creatinine to rule out hypocalcemia and severe renal impairment (alendronate is contraindicated when creatinine clearance falls below 35 mL/min). Vitamin D and calcium adequacy must be confirmed, because alendronate cannot build bone without adequate substrate.

DEXA scan follow-up: Repeat DEXA at 1 to 2 years after starting therapy to confirm a response (stable or increased bone mineral density). The International Society for Clinical Densitometry considers a BMD change of at least 3 to 5% at the lumbar spine a meaningful treatment response. Colorado's major health systems (UCHealth, SCL Health, CommonSpirit) all perform DEXA scanning, and telehealth prescribers in the state can order the scan at any accredited facility.

Dental review before long-term use: The American Dental Association recommends that patients beginning bisphosphonate therapy for osteoporosis inform their dentist. Invasive dental procedures should be completed before starting therapy when possible, though the risk of ONJ from oral alendronate at osteoporosis doses is low enough that most dental work can proceed without interrupting treatment.

Calcium supplementation target for patients on alendronate: 1,000, 1 to 200 mg total daily calcium (diet plus supplement), with vitamin D at 600 to 800 IU daily for adults under 70 and 800 IU daily for those over 70, per National Academy of Medicine recommendations [11].

A Colorado patient filling alendronate at $15 per month cash, adding a store-brand calcium-plus-D supplement at $8 per month, can maintain a complete oral osteoporosis regimen for under $25 monthly without insurance.